Sinopharm Holdings (02096): The new drug application (NDA) for Mavononosavir granules has been accepted by the National Medical Products Administration.

CHINA ON THE GO Finance APP news, Sinopharm Pharmaceutical (02096) announced that on September 3, 2025, the group's new anti-influenza drug, Madou Nosawey capsules (Senlinda), a collaborative product with Jiaxing Andikang Biotechnology Co., Ltd. (Andikang), has been accepted by the National Medical Products Administration (NMPA) for new drug application (NDA), which is used to treat uncomplicated Type A and Type B influenza in children aged 2 to 11. This is the first innovative drug targeting pediatric influenza patients to successfully complete phase III clinical trials and apply for market approval in China.